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Phorate {O,O-diethyl S-[(ethylthio)methyl]
phosphorothioate; trade name: thimet} is an
organophosphate compound used agricultur-
ally, primarily in the production of corn, cot-
ton, and potatoes, to control sap-feeding
insects including various beetles, mites, grubs,
and worms. There are no registered residential
uses. Phorate was ﬁrst registered for use in the
United States in 1959 [U.S. Environmental
Protection Agency (EPA) 2001]. In the
United States, almost 2.5 million acres are
treated annually with 2–3 million pounds of
phorate, making it the sixth most common
organophosphate used (Donaldson et al.
2002).
The currently limited body of literature
does not provide evidence to suggest that
phorate is mutagenic, genotoxic, or carcino-
genic (Bingham et al. 2001; California
Department of Pesticide Regulation 1996; Lin
et al. 1987; Pandita 1986). However, several
epidemiologic studies have found associations
between exposure to organophosphate pesti-
cides and non-Hodgkin lymphoma (NHL)
(Cantor et al. 1992; Zahm et al. 1993) as well
as leukemia (Brown et al. 1990; Clavel et al.
1996), and the International Agency for
Research on Cancer (IARC) considers insecti-
cide application to be an exposure that is prob-
ably carcinogenic in humans (Group 2A)
(IARC 1991). Recent findings from the
Agricultural Health Study (AHS) linking lung
cancer with exposure to diazinon and chlor-
pyrifos (Alavanja et al. 2004) and prostate can-
cer with exposure to chlorpyrifos, coumaphos,
fonofos, and phorate among applicators with a
family history of prostate cancer (Alavanja et al.
2003) prompted us to examine risk for all can-
cers among phorate users in the same cohort
over a longer follow-up period. The aforemen-
tioned insecticides belong to the organothio-
phosphate subgroup, are similar to phorate in
chemical structure, and must be converted in
the body to their bioactive, neurotoxic oxon
forms, which irreversibly inhibit acetylcholine
esterase by phosphorylating a serine hydroxyl
group in the active site of the enzyme (Pope
1999; Sultatos 1994). Little is known of the
carcinogenicity of the oxon species. To our
knowledge, this is the largest epidemiologic
examination of an occupational group exposed
to phorate. 
Methods
Cohort enrollment and follow-up. The AHS
has been described elsewhere (Alavanja et al.
1996). It is a prospective cohort including
52,395 private applicators (farmers) from
Iowa and North Carolina and 4,916 commer-
cial applicators (employees of pest control
companies or persons who apply pesticides as
employees of businesses whose primary
function is not pesticide application) from
Iowa licensed to apply restricted-use pesticides
(82.4% of eligible applicators). Incident
tumors diagnosed between enrollment
(31 December 1993 to 31 December 1997)
and 31 December 2002 were identiﬁed using
population-based tumor registries of both
states. Subjects were censored in the year they
moved out of the state, as determined by an
extensive search of address records, or the year
they died, as determined using the National
Death Index and state death registry records.
Less than 2% of the cohort was lost to follow-
up. The average follow-up time of 7.5 years
represents an increase of 3.2 years over the
previously published prostate cancer paper. All
participants provided informed consent and
the protocol was approved by all appropriate
institutional review boards.
Exposure assessment. Applicators were
given two self-administered questionnaires
upon enrollment. The enrollment question-
naire collected information on days of use per
year, years of use, and decade of ﬁrst use for 22
pesticides, as well as information on ever/never
use of 28 additional pesticides (including phor-
ate); application methods; use of personal pro-
tective equipment (PPE); smoking; alcohol
consumption; farm activities; cancer history in
first-degree relatives; and basic demographic
data. A supplemental take-home questionnaire
collected information on days of use per year,
years of use, and decade of ﬁrst use for the 28
pesticides for which only ever/never use infor-
mation was collected in the enrollment ques-
tionnaire. The take-home questionnaire,
which was completed by 25,291 (44%) of the
participants, also collected additional informa-
tion on work practices, physical activity, med-
ical conditions, and occupational exposures
from nonfarming jobs. Both questionnaires are
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BACKGROUND: We recently reported a link between use of the organophosphate pesticide phorate
and risk of prostate cancer among applicators with a family history of prostate cancer in the
Agricultural Health Study (AHS). 
OBJECTIVE: This finding, together with findings of associations between other organophosphate
pesticides and cancer more broadly, prompted us to examine phorate exposure and overall cancer
incidence in the AHS. Adding 3 years of follow-up and using more detailed exposure information
allowed us to see whether the prostate cancer ﬁnding held. 
METHODS: The AHS is a prospective study of licensed restricted-use pesticide applicators from
North Carolina and Iowa. To our knowledge, this is the largest examination of workers occupa-
tionally exposed to phorate. Pesticide exposure and other information was collected using two self-
administered questionnaires completed from 1993 to 1997. Poisson regression was used to
calculate rate ratios (RR) and 95% conﬁdence intervals (CI), adjusting for potential confounders. 
RESULTS: Phorate use was not related to the incidence of all cancers combined or to any individual
cancer, although we had insufﬁcient numbers to study non-Hodgkin lymphoma or leukemia, which
have been linked to organophosphates in other studies. Although prostate cancer risk was not sig-
niﬁcantly related to phorate use overall or among those without a family history, the risk tended to
increase among applicators with a family history of prostate cancer. The interaction RR was 1.53
(95% CI, 0.99–2.37). 
CONCLUSION: The observed statistical interaction suggests a gene–environment interaction between
family history and phorate exposure in the incidence of prostate cancer, but other explanations are
also possible.
KEY WORDS: agriculture, insecticides, neoplasms, occupational exposure, organophosphorus com-
pounds, organothiophosphorus compounds, pesticides, prostate, phorate. Environ Health Perspect
114:1205–1209 (2006). doi:10.1289/ehp.8911 available via http://dx.doi.org/ [Online 18 April 2006]available at http://www.aghealth.org/question-
naires.html. Applicators who did not return a
questionnaire were generally similar to those
who did with respect to many characteristics
including use of crop insecticides; however,
small differences were observed with respect to
education, age, family size, and vegetable con-
sumption (Tarone et al. 1997). Because of
changing pesticide exposure patterns over time,
pesticide exposure information, pesticide han-
dling practices, and other information was
updated by computer-aided telephone inter-
view from 1999 to 2003. However, because of
the proximity of this interview period to the
end of cancer incidence follow-up, it is unlikely
that this exposure information was etiologically
relevant, and we have not used the interview
information here.
We estimated phorate exposure using
phorate lifetime exposure-days, calculated by
multiplying the frequency of phorate use in an
average year and the number of years of use,
using the midpoints of the questionnaire cate-
gories, and intensity-weighted exposure-days,
calculated by multiplying lifetime exposure-
days by an intensity score calculated using the
following algorithm: intensity score = (mixing
status + application status + equipment repair)
× PPE (Dosemeci et al. 2002). This algorithm
takes into account the effect of exposure-mod-
ifying factors by assigning different weights to
various activities based on the inverse of their
potential contribution to total exposure. For
example, because dermal absorption is often
the most important exposure route for pesti-
cide applicators (Maroni et al. 2000), the use
of chemically resistant gloves was weighted to
confer a greater reduction in intensity score
than any other single item of PPE; the use of
disposable outer clothing reduced the intensity
score to a lesser degree.
Statistical analysis. In contrast to the previ-
ously published tumor-specific analysis of
prostate cancer, which examined prostate can-
cer risk with respect to the ever/never use of
pesticides among all male pesticide applicators
without a prior prostate cancer diagnosis, this
analysis was limited to the subset of applicators
who completed the take-home questionnaire.
Prevalent cancer cases (n = 620) and applica-
tors who did not provide information on phor-
ate exposure or other variables (n = 3,655) were
excluded from this analysis, leaving 5,903
exposed and 15,113 nonexposed applicators.
Participants with missing information tended
to be older and to live in North Carolina. They
were also likely to have missing information for
more than one of the variables listed above.
Cancer sites were selected for analysis if
there were 15 or more incident diagnoses
among phorate-exposed subjects. Speciﬁcally,
these sites were a) all cancers combined;
b) cancers of the colon, lung, and prostate;
and c) the grouping of lymphohematopoietic
cancers, which contains both Hodgkin lym-
phoma and NHL, leukemia, and multiple
myeloma. All statistical analyses were con-
ducted in AHS data release 0412.01 using
Stata version 8 (StataCorp, College Station,
TX; StataCorp 2003). Poisson regression was
used to calculate incidence rate ratios (RR)
and 95% conﬁdence intervals (CI). Both life-
time exposure-days and intensity-weighted
exposure-days for exposed applicators were
categorized into tertiles based on the distribu-
tion of the exposure metric among cancer
cases. To improve resolution at high exposure
levels, we further categorized lifetime exposure-
days by splitting the top tertile at the median
when the split left at least four exposed cases in
each new category. With intensity-weighted
exposure-days used as the exposure measure-
ment, the highest tertile was not split because
of a small number of cases. Finally, because
measures of lifetime cumulative exposure do
not distinguish between infrequent exposure
over a long period of time and more frequent
exposure over a short period of time, which
could make a difference with respect to cancer,
we examined cancer incidence in relation to
average days of use per year categorized as
none, low, and high (low and high categorized
at the median) and stratiﬁed by low and high
years of use (categorized at median).
Both the lifetime and intensity-weighted
exposure-days analyses used the nonexposed
and lowest exposed categories as the reference
group. Cancer-speciﬁc analyses were adjusted
for age as a continuous variable; applicator type
(private or commercial); state of residence
(Iowa or North Carolina); education (≤ high
school graduate, > high school graduate); pack-
years of smoking categorized at the median
(never, ≤ 12, > 12); history of the specific
tumor in ﬁrst-degree relatives (yes or no);  and
use of the five most correlated pesticides
[aldicarb, ethylene dibromide, aldrin, 2,4,5-
trichlorophenoxy propionic acid (2,4,5-TP),
and butylate]. Pearson correlation coefﬁcients
ranged from 0.39 (aldicarb) to 0.36 (butylate).
We categorized use of each correlated pesticide
as never, low, and high usage, employing the
median lifetime exposure-days of use to distin-
guish between low and high usage. Although
the results of these more fully adjusted analyses
and the analyses adjusted for age and smoking
Mahajan et al.
1206 VOLUME 114 | NUMBER 8 | August 2006 • Environmental Health Perspectives
Table 1. Characteristics of applicators by phorate exposure in the AHS (1993–1997) [no. (%)].
Nonexposed Lowest exposed Other exposed
Characteristic n = 15,113 n = 2,407 n = 3,496
Age (years)
< 40 1,981 (13.1) 167 (6.9) 218 (6.2)
40–49 4,161 (27.5) 581 (24.1) 797 (22.8)
50–59 3,630 (24.0) 666 (27.7) 992 (28.4)
≥ 60 5,341 (35.3) 993 (41.3) 1,489 (42.6)
Sex 
Male 14,589 (96.5) 2,387 (99.2) 3,475 (99.4)
Female 524 (3.5) 20 (0.8) 21 (0.6)
State of residence
Iowa 9,783 (64.7) 2,261 (93.9) 2,945 (84.2)
North Carolina 5,330 (35.3) 146 (6.1) 551 (15.8)
Applicator type
Commercial 1,779 (11.8) 101 (4.2) 219 (6.3)
Private 13,334 (88.2) 2,306 (95.8) 3,277 (93.7)
Smoking history
Never 8,262 (54.7) 1,429 (59.4) 1,977 (56.6)
Light (< 12 pack-years) 3,437 (22.7) 542 (22.5) 793 (22.7)
High (≥ 12 pack-years) 3,414 (22.6) 436 (18.1) 726 (20.8)
Education
≤ High school 8,183 (54.2) 1,273 (52.9) 2,050 (58.6)
> High school 6,930 (45.9) 1,134 (47.1) 1,446 (41.4)
Family history of cancera
No 8,257 (58.7) 1,225 (53.0) 1,763 (53.0)
Yes 5,809 (41.3) 1,084 (47.0) 1,561 (47.0)
Alcohola,b
No 5,149 (34.8) 593 (24.9) 944 (27.4)
Yes 9,641 (65.2) 1,789 (75.1) 2,506 (72.6)
Corn farming
No 4,897 (32.4) 149 (6.2) 366 (10.5)
Yes 10,216 (67.6) 2,258 (93.8) 3,130 (89.5)
Use of correlated pesticides
Aldicarb 932 (6.2) 111 (4.6) 444 (12.7)
Ethylene dibromide 687 (4.6) 42 (1.8) 102 (2.9)
Aldrin 1,466 (9.7) 674 (28.0) 1,028 (29.4)
2,4,5-TP 590 (3.9) 122 (5.1) 257 (7.4)
Butylate 3,038 (20.1) 940 (39.1) 1,437 (41.1)
No. of pesticides usedc 10.7 ± 5.9 16.0 ± 5.9 17.0 ± 6.5
aColumn numbers do not add up to total n because of missing information. bBased on reported alcohol consumption in the
past 12 months. cMean ± SD.only were consistent, we present the more fully
adjusted results to address the fact that farmers
are exposed to many agents. To assess trends in
dose–response patterns, we performed linear
trend tests by assigning each exposure category
the median value in that category and treating
the variable as a continuous variable.
To further examine the risk of prostate
cancer, we obtained a parsimonious model by
removing variables that did not alter point
estimates by > 5%, leaving variables for age
and state of residence in the model. We used
an interaction term obtained by taking the
product of family history of prostate cancer
and category of lifetime exposure-days to eval-
uate effect modification between phorate
exposure and family history of prostate cancer. 
Results
Table 1 displays selected characteristics of
applicators by their level of exposure, with
“lowest exposed” referring to those in the low-
est exposed tertile of lifetime exposure-days,
and “other exposed” referring to those in the
remaining tertiles. Overall, those in the nonex-
posed category tended to be less likely to report
producing corn, slightly less likely to report
family history of any cancer, and younger than
those in either of the exposed categories.
Additionally, compared with the exposed
applicators, the nonexposed were also exposed
to signiﬁcantly fewer of the pesticides that were
assessed in the questionnaires. Finally, residents
of North Carolina were more likely than resi-
dents of Iowa to be nonexposed. These differ-
ences between the nonexposed group and
either of the two exposed groups suggest that
the lowest exposed group may be the more
appropriate reference group. 
Table 2 displays adjusted associations
between selected cancer sites and phorate life-
time exposure-days. Phorate use did not
appear to be associated with the incidence of
all cancers combined. For prostate and colon
cancer, the results differed depending on the
reference group. The risk estimates for both
cancers increased monotonically with increas-
ing exposure category relative to the lowest
exposed, but the point estimates and linear
trend tests were not signiﬁcant. However, the
point estimates were not elevated compared
with the nonexposed. Phorate use was not
related to any other examined cancer.
Because phorate use was uncommon in
North Carolina, we repeated our analysis of
all cancers combined, restricting the data to
applicators from Iowa. The results were simi-
lar to those presented above (not shown).
They were not meaningfully different when
we adjusted for lifetime exposure-days to all
pesticides rather than the ﬁve most correlated
pesticides (not shown). Finally, the results
were also consistent when we examined days
of use per year by years of use (not shown).
Namely, we observed slightly elevated but
insigniﬁcant point estimates for prostate and
colon cancer, and no discernible pattern with
any other examined cancer.
Because of the large number of applicators
excluded due to missing information on
covariates, we repeated the analysis in Table 2
on all applicators without missing phorate
exposure information by assigning the miss-
ing covariates an unspecified category (not
shown). The results of this analysis of 17,051
nonexposed and 6,488 exposed applicators
did not substantially differ from the results
presented above. 
Using the intensity-weighted exposure-days
metric, though the number of cases was slightly
reduced because individuals were missing data
on intensity metric covariates, except for
prostate cancer the results were not meaning-
fully different from those presented above (not
shown). Phorate use was not associated with all
cancers combined. Colon cancer risk estimates
were not elevated using the nonexposed refer-
ence group, but compared with the lowest
exposed, they increased monotonically with
exposure category (RR in highest exposed =
1.81; 95% CI, 0.58–5.60). RRs for prostate
cancer were uninﬂuenced by exposure category
regardless of reference group. Phorate use was
not associated with any other examined cancers.
Although too few exposed melanoma
cases (n = 14) prevented inclusion of results in
tables, there were some interesting yet statisti-
cally insigniﬁcant observations. In particular,
melanoma risk estimates tended to increase
with lifetime and intensity-weighted expo-
sure-days category regardless of reference
group. Relative to the unexposed, risk esti-
mates were also elevated among low and high
days of use per year, but only in applicators
with many years of use. 
When prostate cancer risk was stratiﬁed by
family history of prostate cancer, risk estimates
did not increase across categories of lifetime
exposure-days in the stratum of applicators
reporting no family history (Table 3). However,
in applicators with a family history, the risk
estimates tended to increase. The RR in the
highest compared to the lowest exposed was
1.91 (95% CI, 0.86–4.24). The interaction RR
indicated that the risk associated with an
increase in phorate exposure category was 1.53
(95% CI, 0.99–2.37) times higher in those
with a family history of prostate cancer com-
pared with those without. To account for
latency of exposure, we repeated the analysis
among applicators whose ﬁrst use of phorate
was prior to 1980 (not shown). Too few
Occupational phorate exposure and cancer incidence
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Table 2. RRs (95% CIs) for selected cancers by phorate lifetime exposure-days among AHS (1993–1997)
applicators, using nonexposed and lowest exposed applicators as the reference group.
Lifetime exposure-daysa Cases (n) Nonexposed reference Lowest exposed reference
All cancer
0 689 1.00 
> 0–8.75 111 0.84 (0.68–1.04) 1.00
> 8.75–38.75 84 0.94 (0.74–1.19) 1.14 (0.85–1.53)
> 38.75–108.5 62 0.89 (0.68–1.17) 1.08 (0.78–1.49)
> 108.5 38 0.94 (0.67–1.33) 1.19 (0.79–1.78)
p-Trend 0.71 0.53
Lymphohematopoietic cancer
0 72 1.00
> 0–8.75 9 0.59 (0.20–1.12) 1.00
> 8.75–38.75 9 0.88 (0.40–2.03) 1.24 (0.48–3.22)
> 38.75 8 0.64 (0.52–2.17) 0.84 (0.30–2.33)
p-Trend 0.30 0.57
Colon cancer
0 53 1.00
> 0–8.75 6 0.47 (0.20–1.13) 1.00
> 8.75–38.75 7 0.90 (0.40–2.03) 2.22 (0.72–6.83)
> 38.75 10 1.07 (0.49–2.52) 2.48 (0.84–7.36)
p-Trend 0.74 0.18
Lung cancer
0 69 1.00
> 0–8.75 6 0.81 (0.34–1.96) 1.00
> 8.75–38.75 5 1.00 (0.39–2.61) 1.14 (0.34–3.84)
> 38.75–108.5 4 0.82 (0.29–2.37) 0.85 (0.22–3.23)
> 108.5 4 0.95 (0.31–2.94) 0.63 (0.14–2.86)
p-Trend 0.91 0.47
Prostate cancer
0 286 1.00
> 0–8.75 53 0.89 (0.65–1.21) 1.00
> 8.75–38.75 38 0.91 (0.64–1.29) 1.08 (0.71–1.66)
> 38.75–108.5 28 0.92 (0.62–1.38) 1.16 (0.73–1.86)
> 108.5 16 0.93 (0.55–1.57) 1.31 (0.72–2.37)
p-Trend 0.78 0.40
p-Trend, p-value for trend test. Incidence RRs adjusted for age, state of residence, applicator type, education, family his-
tory of site-speciﬁc cancer, smoking, and use of aldicarb, ethylene dibromide, aldrin, 2,4,5-TP, and butylate. 
aLifetime exposure-days = years of use × days of use per year. Mahajan et al.
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exposed applicators with a family history of
prostate cancer prevented us from conducting
the same analysis among those whose ﬁrst expo-
sure was after 1980. The results were consistent
with those presented above. 
For comparison with the previously pub-
lished prostate cancer analysis (Alavanja et al.
2003), we repeated the analysis using method-
ology comparable to that used in the previ-
ously published prostate cancer study. That is,
we used logistic regression to calculate odds
ratios (OR) among all enrolled male applica-
tors without prior history of prostate cancer,
categorizing phorate exposure as ever/never.
We used the cross product of ever/never phor-
ated exposure and family history of prostate
cancer to assess effect modification (not
shown). We found that the age-adjusted
prostate cancer risk was signiﬁcantly elevated
in those with a family history of prostate
cancer (OR = 1.53; 95% CI, 1.09–2.14;
249 exposed cases), but not in those without
(OR = 1.11; 95% CI, 0.95–1.31; 73 exposed
cases). The interaction OR was 1.40 (95% CI,
0.96–2.04), adjusted for age and family his-
tory of prostate cancer. The corresponding
interaction OR from the previous paper was
1.64 (95% CI, 1.02–2.63).
Discussion
Phorate use was not related to the occurrence of
all cancers combined in this study. Although
previous studies have observed suggestive
increases in the risk of NHL and leukemia asso-
ciated with the use of organophosphate pesti-
cides (Brown et al. 1990; Cantor et al. 1992;
Clavel et al. 1996; Zahm et al. 1993), the risk
of lymphohematopoietic cancers overall was
not associated with phorate use in this cohort.
Too few exposed cases of NHL, leukemia,
Hodgkin lymphoma, and multiple myeloma
prevented evaluations of these cancers individu-
ally. As the lymphohematopoietic grouping
may not be etiologically homogeneous, it
would be prudent for follow-up studies to
examine each cancer separately as more cancer
cases develop in the cohort.
Prostate cancer risk was not significantly
associated with phorate use. However, among
applicators reporting a family history of
prostate cancer, the risk associated with phor-
ate exposure was elevated, whereas there was
no corresponding increase among those with-
out a family history. An elevated interaction
term of similar magnitude was observed in an
examination of prostate cancer in an article by
Alavanja et al. (2003). The study conducted
here is a chemical-speciﬁc analysis carried out
on 135 phorate-exposed prostate cancer cases
using information on lifetime exposure-days
and intensity-weighted lifetime-exposure days
to examine dose–response relationships. In
contrast, the previously published prostate
cancer study was a tumor-speciﬁc analysis and
in quantifying phorate use as ever/never use
could not examine dose–response trends. In
addition, this study was carried out over a
longer average follow-up period of 7.5 years,
compared with 4.3 years. Despite the analytic
differences, the results are generally consistent
with the previous paper. 
Family history of prostate cancer is strongly
and consistently linked to prostate cancer in
the scientiﬁc literature (Bostwick et al. 2004).
For example, monozygotic twins have higher
prostate cancer concordance than dizygotic
twins (Gronberg et al. 1994). Risk is elevated
several-fold in individuals with an affected
father or brother (Glover et al. 1998; Spitz
et al. 1991; Steinberg et al. 1990; Whittemore
et al. 1995) and may increase if a greater num-
ber of first-degree relatives are affected
(Steinberg et al. 1990). Finally, cancers in indi-
viduals with affected family members occur at
younger ages compared with individuals with-
out affected family members (Bratt et al.
1999; Gronberg et al. 1999). Farming occupa-
tion has also been modestly but signiﬁcantly
associated with prostate cancer (Blair et al.
1985; Checkoway et al. 1987; Sharma-Wagner
et al. 2000; van der Gulden and Vogelzang
1996; Van Maele-Fabry and Willems 2004). In
particular, the results of several studies suggest
that this association may be caused by exposure
to pesticides (Potti et al. 2003). Signiﬁcant asso-
ciations were found specifically among those
individuals who were ever employed in the
mixing and application of pesticides (Fleming
et al. 1999; Settimi et al. 2001), and cancer risk
increased with both the number of days of pes-
ticides applied per year (van der Gulden et al.
1995) and the number of acres sprayed with
herbicides in 1 year (Morrison et al. 1993). 
Although a number of exposures shared in
common between study subjects and their ﬁrst-
degree relatives could lead to a statistical inter-
action between phorate use and family history
of prostate cancer, the presence of family his-
tory of prostate cancer may serve as a surrogate
for an inherited genetic trait, such as a polymor-
phism in a metabolism enzyme. The active
form of most organophosphates, including
phorate and chlorpyrifos, is the corresponding
oxon (Pope 1999; Sultatos 1994), and both of
these insecticides are metabolized using many
of the same enzymes (Tang et al. 2001; Usmani
et al. 2004). Polymorphic variants of several
cytochrome P450 isoforms vary considerably in
their ratio of bioactivation to detoxiﬁcation of
chlorpyrifos (Dai et al. 2001; Tang et al. 2001).
Thus, it is possible that the observation of an
interaction of family history and phorate expo-
sure reﬂects the presence of an inherited poly-
morphism that alters the balance between
bioactivation and detoxiﬁcation in the body. 
There are some limitations of this study. At
this time, investigation of certain cancers is
hindered by small numbers of exposed cases,
making it difficult to analyze some cancers.
However, as the cohort ages, more cancer cases
will accrue and allow for more statistically
powerful investigations. Additionally, some
exposure misclassification is likely, although
there is no reason to believe that it occurred
differentially between cancer cases and cancer-
free subjects, because exposure information was
gathered prior to disease onset.
Another general limitation of studies of pes-
ticide applicators is that few applicators are
exposed to one agent. To attempt to control for
potential confounding from other pesticides,
the risk estimates were adjusted for use of the
five pesticides most correlated with phorate.
However, the use of other pesticides did not
likely confound the observed relationships
because the correlation coefficients, which
ranged between 0.36 for butylate and 0.39 for
aldicarb, were not very high. Moreover, risk
estimates were similar when they were adjusted
for cumulative lifetime exposure-days to all pes-
ticides. An examination of pesticide usage and
speciﬁc farming activities found that these activ-
ities likely resulted in minimal confounding
(Coble et al. 2002). 
Table 3. Incidence RRsa (95% CIs) for prostate cancer by phorate lifetime exposure-days after stratiﬁca-
tion by family history of prostate cancer among male AHS (1993–1997) applicators.
Lifetime exposure-daysb Cases (n) Nonexposed reference Lowest exposed reference
No family history
0 270 1.00
> 0–8.75 49 1.01 (0.74–1.39) 1.00
> 8.75–24.5 35 1.05 (0.73–1.51) 1.03 (0.67–1.60)
> 24.5 35 0.91 (0.64–1.30) 0.92 (0.59–1.43)
p-Trend 0.66 0.69
Family history
0 56 1.00
> 0–8.75 10 0.69 (0.35–1.39) 1.00
> 8.75–24.5 11 1.27 (0.65–2.49) 1.90 (0.80–4.50)
> 24.5 17 1.48 (0.85–2.58) 1.91 (0.86–4.24)
p-Trend 0.11 0.16
Interactionc 1.18 (0.96–1.44) 1.53 (0.99–2.37)
p-Trend, p-value for trend test.
aRRs adjusted for age and state of residence. bLifetime exposure-days = years of use × days of use per year. cRR and 95%
CI for the cross product of family history of prostate cancer and lifetime exposure-days category, adjusted for age, state
of residence, and family history of prostate cancer. Occupational phorate exposure and cancer incidence
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The exposure measures in this study are an
improvement. Whereas previous studies of pes-
ticide exposures were limited to qualitative
exposure measures, this study attempts to quan-
tify cumulative lifetime exposure by incorporat-
ing measures of frequency, duration, and
intensity of exposure to speciﬁc pesticides. The
measure of intensity used information such as
application methods and PPE use to calculate a
more precise measurement of actual exposure.
Furthermore, the rate of recruitment and fol-
low-up of participants was very high, as 82% of
eligible participants enrolled, and < 2% were
lost to follow-up. Although not all take-home
questionnaires were returned, the measured dif-
ferences between respondents and nonrespon-
dents were not likely to be influential here
(Tarone et al. 1997). Thus, the applicators
returning the take-home questionnaire were
likely representative of the overall cohort in
terms of cancer risk. 
In summary, no clear association between
phorate and any cancer was observed in this
study. However, the study findings are not
inconsistent with the hypothesis that there is
an interaction between phorate exposure and
family history of prostate cancer in the inci-
dence of this cancer, suggesting that there
may be an inherited genetic variability that
alters susceptibility to prostate cancer. Future
analyses of the AHS to further investigate the
relationship between phorate exposure and
the risk of prostate cancer are warranted. 
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